Promoting Precision Addiction Management (PAM) to Combat the Global Opioid Crisis.

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Dopamine is crucial for reward dependence, but its clinical modulation for addiction treatment is debated.
• Existing treatments often block dopamine, potentially hindering long-term recovery.
• Reward Deficiency Syndrome (RDS) is proposed as the core phenotype of all addictive behaviors.

Purpose of the Study:

• To propose a novel therapeutic paradigm for addiction.
• To advocate for early genetic identification of addiction risk.
• To challenge current opioid and alcohol crisis management strategies.

Main Methods:

• Review of existing literature on dopamine and addiction.
• Proposal of a biphasic treatment approach: short-term blockade and long-term upregulation.
• Integration of genetic testing (Genetic Addiction Risk Score - GARS™) and comprehensive drug screening (Comprehensive Analysis of Reported Drugs - CARD™).

Main Results:

• Current FDA-approved medications primarily focus on dopamine blockade.
• A biphasic approach enhancing functional connectivity is suggested as a more effective strategy.
• Treating Reward Deficiency Syndrome (RDS) is identified as the key to managing addictive behaviors.

Conclusions:

• A paradigm shift towards biphasic dopamine modulation is necessary for effective addiction treatment.
• Precision Addiction Management™, incorporating genetic and drug screening, offers a more promising solution than current approaches.
• Addressing RDS is critical for combating the global opioid and alcohol crisis.